Search

Displaying results 911 - 920 of 10000 in total
  1. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

    Synonyms: (±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol, 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
  2. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Mixtures: Drixoral Day/night - Srt/tabs, Dologesic NFSynonyms: 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
  3. Drug

    Ephedra sinica root

    go.drugbank.com/drugs/DB01363
    ApprovedNutraceutical

    The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for

    Mixtures: Miller's Formula No. 1
  4. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Analgesics, Non-Narcotic
  5. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. … Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.

    Synonyms: Interferon alfa-n1, Interferon alpha-n1 (INS)Categories: interferon alfa-n1
  6. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. … This drug is developed by Ceregene and currently under phase I of clinical trial.

  7. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. … gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption and exposure, although the formal mechanism of action of quaternary ammonium compounds like n-alkyl

    Synonyms: N-alkyl ethylbenzyl dimethyl ammonium (C12-C14), N-alkyl ethylbenzyl dimethyl ammonium (C12-C14) cationSalts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)
  8. Target

    Non-secretory ribonuclease

    go.drugbank.com/bio_entities/BE0001306
    TargetHumans

    This is a non-secretory ribonuclease. It is a pyrimidine specific nuclease with a slight preference for U. Cytotoxin and helminthotoxin. Selectively chemotactic for dendritic cells.

    Polypeptides: Non-secretory ribonuclease
  9. Target

    Non-heme chloroperoxidase

    go.drugbank.com/bio_entities/BE0003176
    TargetStreptomyces aureofaciens

    Polypeptides: Non-heme chloroperoxidase
  10. Target

    Non-lysosomal glucosylceramidase

    go.drugbank.com/bio_entities/BE0020281
    TargetHumans

    Non-lysosomal glucosylceramidase that catalyzes the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) to free glucose and ceramides (such as N-acylsphing-4

    Polypeptides: Non-lysosomal glucosylceramidaseSynonyms: Non-lysosomal glycosylceramidase, Non-lysosomal galactosylceramidase